Advertisement Scroll To Keep Reading
South Africa

History made as first SA child is vaccinated in CoronaVac trial | Muhabarishaji News

Advertisement Scroll To Keep Reading
The first South African child was vaccinated against COVID-19 with the Sinovac vaccine CoronaVac on Friday, 10 September. South Africa is one of five countries participating in the phase III trial that involves 14 000 children under the age of 18 globally. The Numolux Group, which are Sinovac Biotech’s local representatives, are running the trial in the country.

CORONAVAC TRIAL KICKS OFF

History was made at the Sefako Makgatho Health Science University in Pretoria on Friday when the first two children – aged between 12 and 17 – received the first of two CoronaVac jabs at the university’s MeCRU Clinical Research Unit.

Advertisement Scroll To Keep Reading

The doses of vaccine will be given 28 days apart and the study is expected to last between 13 to 14 months. The children are just two out of 2000 South African youths – aged between 6 months and 17 years old – participating in the CoronaVac trial, which has been approved by the South African Health Products Regulatory Authority (SAHPRA) and the World Health Organization (WHO).

PRETORIA, SOUTH AFRICA – SEPTEMBER 10: The first child to be vaccinated at MeCRU Clinical Research Unit in South Africa on September 10, 2021 in Pretoria, South Africa.

China’s Sinovac Biotec will trial its COVID-19 vaccine on children and adolescents aged 6 months to 17 years, the trial has been approved by South African drugs regulator SAHPRA .The study will evaluate the efficacy, immunogenicity and safety of the CoronaVac vaccine. .(Photo by Gallo Images/Alet Pretorius)

PRETORIA, SOUTH AFRICA – SEPTEMBER 10: The second child to be vaccinated at MeCRU Clinical Research Unit in South Africa on September 10, 2021 in Pretoria, South Africa.

China’s Sinovac Biotec will trial its COVID-19 vaccine on children and adolescents aged 6 months to 17 years, the trial has been approved by South African drugs regulator SAHPRA .The study will evaluate the efficacy, immunogenicity and safety of the CoronaVac vaccine. .(Photo by Gallo Images/Alet Pretorius)

Numolux said it has partnered with 7 clinical research sites across South Africa where the vaccinations will take place.

Other children from Chile, the Philippines, Malaysia and Kenya are also participating in the trial. The conditional use of CoronaVac in South Africa was approved in July 2021 by SAHPRA.

“The primary objective of the study is to evaluate the efficacy of two doses of CoronaVac against confirmed symptomatic COVID-19 cases in children and adolescents …efficacy will also be evaluated against hospitalisation and severe COVID-19,” said Sinovac and Numolux on Thursday, 9 September, when the trial was announced in South Africa.

Advertisement Scroll To Keep Reading

Related Articles

Back to top button

AdBlock Detected

If you enjoy our content, Please support our site by disabling your adblocker. We depend on ad revenue to keep creating quality content for you to enjoy for free.